Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies

Status:

Opening Soon

Observational

Phase

N/A

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

N/A

Investigational

Product

n/a

Treatment Arms

o Diagnostic Test: FDG Positron emission tomography (PET) scan

o Diagnostic Test: PSMA Positron emission tomography (PET) scan

o Diagnostic Test: OCTREOTATE Positron emission tomography (PET) scan

o Other: Optional Bone or soft-tissue biopsies